# IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07722494/  
OnCo record `nct07722494` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of IBI363, Bevacizumab in colorectal cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.

## Summary

IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer is a phase 3 interventional study registered as NCT07722494 by Innovent Biologics (Suzhou) Co. Ltd., with 550 participants planned, started 2026-07-31 and due to reach its primary completion in 2028-10-31. Interventions recorded: IBI363 + bevacizumab, Investigator's choice of therapy. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07722494
- Phase: 3
- Setting: A Randomized, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of IBI363 in Combination With Bevacizumab Versus Investigator's Choice of Therapy in Participants With Advanced Colorectal Cancer Who Have Failed or Are Intolerant to Standard Care of Therapy
- Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- Enrolled: 550

## Sources

- ClinicalTrials.gov NCT07722494: https://clinicaltrials.gov/study/NCT07722494

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [IBI363](https://onco.cc/drugs/ibi363/)
- companies: [Innovent Biologics](https://onco.cc/companies/innovent/)

---
JSON: https://onco.cc/api/v1/entities/nct07722494.json